Skip to main content
PT

Prism TPO

Prism TPO operates a purchasing organization that gives independent oncology practices upfront, transparent price quotes for oncology drugs by removing retrospective rebates and other legacy pricing components. The platform aggregates contracts from 17 pharmaceutical manufacturers covering 36 drug agreements and provides real‑time pricing dashboards, automated rebate administration, and API integration to streamline procurement and cost monitoring.

Updated 2 months ago

Funding

Funding not disclosed

Funding rounds are not available yet.

Founders

Product

Problem

Independent medical and oncology practices often spend extensive time navigating opaque drug pricing structures, hidden rebates, and complex contractual terms, which hampers efficient procurement and reduces focus on patient care.

Solution

Prism TPO provides a purchasing organization that delivers upfront, transparent drug pricing by stripping out more than 80 % of traditional pricing components such as retrospective distribution rebates. Practices receive a single, predictable price quote for each oncology medication, eliminating guesswork and hidden fees. The platform aggregates contracts from a network of 17 pharmaceutical manufacturers covering 36 oncology drug agreements, giving members access to competitive rates at scale. Real‑time pricing data and savings analytics enable practices to quantify cost impact across all practice sizes. By acting as a trusted intermediary, Prism TPO simplifies rebate management, contract execution, and ongoing performance monitoring, allowing clinicians to redirect time toward patient treatment.

Target Audience

The primary customers are independent oncology practices and other stand‑alone medical providers that purchase oncology drugs and seek transparent, predictable pricing.

Features

  • Upfront price quotes with no hidden fees, derived by removing retrospective rebates and other legacy pricing components
  • Consolidated contract marketplace linking independent practices with 17 pharma manufacturers and 36 oncology drug agreements
  • Automated rebate and contract administration tools that reduce manual processing and audit risk
  • Real‑time pricing dashboard delivering quantifiable savings metrics and utilization insights for each therapy
  • Pharmacy, Therapeutics & Economics (PTE) Committee oversight to ensure clinical relevance and economic accountability of contracts
  • Data‑driven performance monitoring that tracks therapy adoption and cost trends across the member network
  • Integration‑ready API for seamless connection with practice procurement and inventory systems
This profile is AI-generated and may contain inaccuracies.